Xiangxue Pharmaceutical
Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of modern Chinese medicine in China. The company provides ban lan gen granules, flu-over liquid, juhong cough-off liquid, and juhong cough-off decoction; chinese herbal, such as huazhou citri grandis, goji berry, chrysanthemum, and rose dried buds; beverages, including king sarsae, asia sarsae, diet s… Read more
Xiangxue Pharmaceutical (300147) - Total Assets
Latest total assets as of September 2025: CN¥7.36 Billion CNY
Based on the latest financial reports, Xiangxue Pharmaceutical (300147) holds total assets worth CN¥7.36 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Xiangxue Pharmaceutical - Total Assets Trend (2007–2024)
This chart illustrates how Xiangxue Pharmaceutical’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Xiangxue Pharmaceutical - Asset Composition Analysis
Current Asset Composition (December 2024)
Xiangxue Pharmaceutical's total assets of CN¥7.36 Billion consist of 21.4% current assets and 78.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 1.8% |
| Accounts Receivable | CN¥901.76 Million | 12.0% |
| Inventory | CN¥340.92 Million | 4.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.06 Billion | 14.1% |
| Goodwill | CN¥199.72 Million | 2.7% |
Asset Composition Trend (2007–2024)
This chart illustrates how Xiangxue Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Xiangxue Pharmaceutical's current assets represent 21.4% of total assets in 2024, an increase from 18.3% in 2007.
- Cash Position: Cash and equivalents constituted 1.8% of total assets in 2024, down from 8.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 8.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 14.1% of total assets.
Xiangxue Pharmaceutical Competitors by Total Assets
Key competitors of Xiangxue Pharmaceutical based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Xiangxue Pharmaceutical - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Xiangxue Pharmaceutical generates 0.25x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Xiangxue Pharmaceutical is currently not profitable relative to its asset base.
Xiangxue Pharmaceutical - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.27 | 0.36 | 0.85 |
| Quick Ratio | 0.22 | 0.28 | 0.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-4.43 Billion | CN¥ -3.30 Billion | CN¥ -659.31 Million |
Xiangxue Pharmaceutical - Advanced Valuation Insights
This section examines the relationship between Xiangxue Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.13 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | -9.4% |
| Total Assets | CN¥7.50 Billion |
| Market Capitalization | $593.40 Million USD |
Valuation Analysis
Below Book Valuation: The market values Xiangxue Pharmaceutical's assets below their book value (0.08 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Xiangxue Pharmaceutical's assets decreased by 9.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Xiangxue Pharmaceutical (2007–2024)
The table below shows the annual total assets of Xiangxue Pharmaceutical from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥7.50 Billion | -9.45% |
| 2023-12-31 | CN¥8.28 Billion | -11.47% |
| 2022-12-31 | CN¥9.35 Billion | -17.82% |
| 2021-12-31 | CN¥11.38 Billion | +16.39% |
| 2020-12-31 | CN¥9.78 Billion | +15.56% |
| 2019-12-31 | CN¥8.46 Billion | -1.90% |
| 2018-12-31 | CN¥8.63 Billion | -8.63% |
| 2017-12-31 | CN¥9.44 Billion | +18.18% |
| 2016-12-31 | CN¥7.99 Billion | +71.73% |
| 2015-12-31 | CN¥4.65 Billion | +29.64% |
| 2014-12-31 | CN¥3.59 Billion | +3.27% |
| 2013-12-31 | CN¥3.47 Billion | +17.83% |
| 2012-12-31 | CN¥2.95 Billion | +53.50% |
| 2011-12-31 | CN¥1.92 Billion | +4.03% |
| 2010-12-31 | CN¥1.85 Billion | +164.44% |
| 2009-12-31 | CN¥698.31 Million | +26.63% |
| 2008-12-31 | CN¥551.47 Million | -0.35% |
| 2007-12-31 | CN¥553.43 Million | -- |